Rocket Pharmaceuticals (RCKT)

Rocket Pharmaceuticals (RCKT) Stock Price & Analysis


RCKT Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$14.86 - $24.65
Previous Close$20.49
Average Volume (3M)1.12M
Market Cap
Enterprise Value$1.37B
Total Cash (Recent Filing)$307.04M
Total Debt (Recent Filing)$25.39M
Price to Earnings (P/E)-6.1
Nov 08, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.34
Shares Outstanding80,525,531
10 Day Avg. Volume1,104,786
30 Day Avg. Volume1,116,585
Standard Deviation0.18
Financial Highlights & Ratios
Price to Book (P/B)4.88
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-8.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.14K
Enterprise Value/Ebitda-5.44
Price Target Upside163.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Rocket Pharmaceuticals’s price range in the past 12 months?
Rocket Pharmaceuticals lowest stock price was $14.86 and its highest was $24.65 in the past 12 months.
    What is Rocket Pharmaceuticals’s market cap?
    Currently, no data Available
    When is Rocket Pharmaceuticals’s upcoming earnings report date?
    Rocket Pharmaceuticals’s upcoming earnings report date is Nov 08, 2023 which is in 36 days.
      How were Rocket Pharmaceuticals’s earnings last quarter?
      Rocket Pharmaceuticals released its earnings results on Aug 10, 2023. The company reported -$0.82 earnings per share for the quarter, missing the consensus estimate of -$0.809 by -$0.011.
        Is Rocket Pharmaceuticals overvalued?
        According to Wall Street analysts Rocket Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Rocket Pharmaceuticals pay dividends?
          Rocket Pharmaceuticals does not currently pay dividends.
          What is Rocket Pharmaceuticals’s EPS estimate?
          Rocket Pharmaceuticals’s EPS estimate is -$0.82.
            How many shares outstanding does Rocket Pharmaceuticals have?
            Rocket Pharmaceuticals has 80,525,530 shares outstanding.
              What happened to Rocket Pharmaceuticals’s price movement after its last earnings report?
              Rocket Pharmaceuticals reported an EPS of -$0.82 in its last earnings report, missing expectations of -$0.809. Following the earnings report the stock price went down -1.061%.
                Which hedge fund is a major shareholder of Rocket Pharmaceuticals?
                Among the largest hedge funds holding Rocket Pharmaceuticals’s share is Maverick Capital ltd. It holds Rocket Pharmaceuticals’s shares valued at 87M.


                  Rocket Pharmaceuticals Stock Smart Score

                  The Rocket Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Rocket Pharmaceuticals

                  Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of first-in-class gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The firm's clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded in 1999 and is headquartered in New York, NY.


                  Top 5 ETFs holding RCKT

                  Market Value
                  Smart Score
                  Vanguard Total Stock Market ETF
                  Vanguard Health Care ETF
                  Schwab U.S. Broad Market ETF
                  Fidelity Nasdaq Composite Index ETF
                  Vanguard Russell 3000 ETF
                  Up to five ETFs with an Outperform Smart Score that hold RCKT. The ETFs are listed according to market value of RCKT within the ETF

                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Bellicum Pharmaceuticals
                  Editas Medicine

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis